written on 08.05.2014

J&J, Roche, Celgene and others power new cancer-drug wave


In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. But that's just what the IMS Institute for Healthcare Informatics is doing in its latest report on the pharma business.